The direct and weight-independent actions of some new obesity pharmacotherapies in ectopic fat of specific organs may further enhance the potential for tailored treatment choices based on patients complications
While those drugs pose more risk to patients than GLP-1s, the companies were also accused of improperly screening potential customers
Axxams GLP-1 secretion assay: metabolic drug discovery from a different perspective Studies have shown that fatty acids and other endogenous ligands may engage with relevant GPCRs, including GPR40, GPR120, GPR119 and TGR5, to promote GLP-1 secretion
Focus on the long-term trajectory rather than weekly results during the escalation phase
If side effects occur, consult your healthcare provider
For Research Use Only Not intended to diagnose, treat, cure, or prevent any disease